Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02004522
Title A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications

chronic lymphocytic leukemia

Therapies

Duvelisib

Ofatumumab

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUT


No variant requirements are available.